Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the media report relating to the allegation of an incident of potential insider dealing in the Company’s shares by an unconnected private individual in 2020.
The Company confirms that it was made aware of this allegation by, and at their request, is helping the relevant Irish authorities in respect of this allegation.
Dublin and London-listed pharmaceutical company @OpenOrphan confirmed its shares are at the centre of alleged insider trading under Garda investigation. However, the company has said the allegations relate to a private individual unconnected to the firm. https://t.co/SbcOsTkRiU https://t.co/rjyBIHSMQK pic.twitter.com/Ov5D3x3PdB
— Share_Talk ™ (@Share_Talk) September 15, 2022
The Board of Open Orphan is satisfied that there are no implications for the Company in the resolution of this allegation and confirms that no employee, executive, director or anyone connected with the Company had any involvement whatsoever in this matter nor are they suspected of any wrongdoing.
For further information please contact:
Open Orphan plc
+44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
